vs
Side-by-side financial comparison of Stryker Corporation (SYK) and US Foods Holding Corp. (USFD). Click either name above to swap in a different company.
US Foods Holding Corp. is the larger business by last-quarter revenue ($9.8B vs $7.2B, roughly 1.4× Stryker Corporation). Stryker Corporation runs the higher net margin — 11.8% vs 1.9%, a 10.0% gap on every dollar of revenue. On growth, Stryker Corporation posted the faster year-over-year revenue change (11.4% vs 3.3%). Stryker Corporation produced more free cash flow last quarter ($1.9B vs $159.0M). Over the past eight quarters, Stryker Corporation's revenue compounded faster (16.9% CAGR vs 4.6%).
The Stryker is a family of eight-wheeled armored fighting vehicles derived from the Canadian LAV III, which in turn derived from the Swiss Mowag Piranha. Stryker vehicles are produced by General Dynamics Land Systems-Canada (GDLS-C) for the United States Army in a plant in London, Ontario. It has four-wheel drive (8×4) and can be switched to all-wheel drive (8×8).
US Foods Holding Corp. is an American food service distributor. It is the second-largest food service distributor in the U.S., after Sysco. The company supplies 250,000 locations including independent restaurants, chain restaurants, healthcare, hospitality, and educational institutions.
SYK vs USFD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.2B | $9.8B |
| Net Profit | $849.0M | $184.0M |
| Gross Margin | 64.5% | 17.6% |
| Operating Margin | 25.2% | 3.3% |
| Net Margin | 11.8% | 1.9% |
| Revenue YoY | 11.4% | 3.3% |
| Net Profit YoY | 55.5% | 178.8% |
| EPS (diluted) | $2.20 | $0.82 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.2B | $9.8B | ||
| Q3 25 | $6.1B | $10.2B | ||
| Q2 25 | $6.0B | $10.1B | ||
| Q1 25 | $5.9B | $9.4B | ||
| Q4 24 | $6.4B | $9.5B | ||
| Q3 24 | $5.5B | $9.7B | ||
| Q2 24 | $5.4B | $9.7B | ||
| Q1 24 | $5.2B | $8.9B |
| Q4 25 | $849.0M | $184.0M | ||
| Q3 25 | $859.0M | $153.0M | ||
| Q2 25 | $884.0M | $224.0M | ||
| Q1 25 | $654.0M | $115.0M | ||
| Q4 24 | $546.0M | $66.0M | ||
| Q3 24 | $834.0M | $148.0M | ||
| Q2 24 | $825.0M | $198.0M | ||
| Q1 24 | $788.0M | $82.0M |
| Q4 25 | 64.5% | 17.6% | ||
| Q3 25 | 63.6% | 17.2% | ||
| Q2 25 | 63.8% | 17.6% | ||
| Q1 25 | 63.8% | 17.3% | ||
| Q4 24 | 64.9% | 17.6% | ||
| Q3 24 | 64.0% | 17.1% | ||
| Q2 24 | 63.0% | 17.6% | ||
| Q1 24 | 63.6% | 16.7% |
| Q4 25 | 25.2% | 3.3% | ||
| Q3 25 | 18.7% | 2.8% | ||
| Q2 25 | 18.5% | 3.7% | ||
| Q1 25 | 14.3% | 2.4% | ||
| Q4 24 | 9.0% | 3.2% | ||
| Q3 24 | 19.7% | 2.9% | ||
| Q2 24 | 19.4% | 3.6% | ||
| Q1 24 | 18.5% | 1.8% |
| Q4 25 | 11.8% | 1.9% | ||
| Q3 25 | 14.2% | 1.5% | ||
| Q2 25 | 14.7% | 2.2% | ||
| Q1 25 | 11.1% | 1.2% | ||
| Q4 24 | 8.5% | 0.7% | ||
| Q3 24 | 15.2% | 1.5% | ||
| Q2 24 | 15.2% | 2.0% | ||
| Q1 24 | 15.0% | 0.9% |
| Q4 25 | $2.20 | $0.82 | ||
| Q3 25 | $2.22 | $0.67 | ||
| Q2 25 | $2.29 | $0.96 | ||
| Q1 25 | $1.69 | $0.49 | ||
| Q4 24 | $1.41 | $0.28 | ||
| Q3 24 | $2.16 | $0.61 | ||
| Q2 24 | $2.14 | $0.80 | ||
| Q1 24 | $2.05 | $0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.0B | $41.0M |
| Total DebtLower is stronger | — | $5.1B |
| Stockholders' EquityBook value | $22.4B | $4.3B |
| Total Assets | $47.8B | $13.9B |
| Debt / EquityLower = less leverage | — | 1.18× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.0B | $41.0M | ||
| Q3 25 | $3.3B | $56.0M | ||
| Q2 25 | $2.4B | $61.0M | ||
| Q1 25 | $2.3B | $101.0M | ||
| Q4 24 | $3.7B | $59.0M | ||
| Q3 24 | $3.9B | $81.0M | ||
| Q2 24 | $1.9B | $405.0M | ||
| Q1 24 | $2.3B | $267.0M |
| Q4 25 | — | $5.1B | ||
| Q3 25 | — | $4.8B | ||
| Q2 25 | — | $4.7B | ||
| Q1 25 | — | $4.7B | ||
| Q4 24 | — | $4.8B | ||
| Q3 24 | — | $4.7B | ||
| Q2 24 | — | $4.6B | ||
| Q1 24 | — | $4.6B |
| Q4 25 | $22.4B | $4.3B | ||
| Q3 25 | $21.8B | $4.5B | ||
| Q2 25 | $21.2B | $4.6B | ||
| Q1 25 | $20.9B | $4.6B | ||
| Q4 24 | $20.6B | $4.5B | ||
| Q3 24 | $20.1B | $4.6B | ||
| Q2 24 | $19.8B | $5.0B | ||
| Q1 24 | $19.2B | $4.8B |
| Q4 25 | $47.8B | $13.9B | ||
| Q3 25 | $47.1B | $14.0B | ||
| Q2 25 | $46.3B | $13.8B | ||
| Q1 25 | $46.0B | $13.7B | ||
| Q4 24 | $43.0B | $13.4B | ||
| Q3 24 | $43.8B | $13.5B | ||
| Q2 24 | $39.1B | $13.7B | ||
| Q1 24 | $39.4B | $13.4B |
| Q4 25 | — | 1.18× | ||
| Q3 25 | — | 1.08× | ||
| Q2 25 | — | 1.02× | ||
| Q1 25 | — | 1.02× | ||
| Q4 24 | — | 1.06× | ||
| Q3 24 | — | 1.01× | ||
| Q2 24 | — | 0.92× | ||
| Q1 24 | — | 0.95× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.1B | $293.0M |
| Free Cash FlowOCF − Capex | $1.9B | $159.0M |
| FCF MarginFCF / Revenue | 26.1% | 1.6% |
| Capex IntensityCapex / Revenue | 3.7% | 1.4% |
| Cash ConversionOCF / Net Profit | 2.52× | 1.59× |
| TTM Free Cash FlowTrailing 4 quarters | $4.3B | $959.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1B | $293.0M | ||
| Q3 25 | $1.5B | $351.0M | ||
| Q2 25 | $1.1B | $334.0M | ||
| Q1 25 | $250.0M | $391.0M | ||
| Q4 24 | $1.9B | $283.0M | ||
| Q3 24 | $1.5B | $270.0M | ||
| Q2 24 | $633.0M | $482.0M | ||
| Q1 24 | $204.0M | $139.0M |
| Q4 25 | $1.9B | $159.0M | ||
| Q3 25 | $1.4B | $236.0M | ||
| Q2 25 | $928.0M | $257.0M | ||
| Q1 25 | $127.0M | $307.0M | ||
| Q4 24 | $1.7B | $178.0M | ||
| Q3 24 | $1.3B | $190.0M | ||
| Q2 24 | $481.0M | $413.0M | ||
| Q1 24 | $37.0M | $52.0M |
| Q4 25 | 26.1% | 1.6% | ||
| Q3 25 | 22.3% | 2.3% | ||
| Q2 25 | 15.4% | 2.5% | ||
| Q1 25 | 2.2% | 3.3% | ||
| Q4 24 | 25.9% | 1.9% | ||
| Q3 24 | 23.7% | 2.0% | ||
| Q2 24 | 8.9% | 4.3% | ||
| Q1 24 | 0.7% | 0.6% |
| Q4 25 | 3.7% | 1.4% | ||
| Q3 25 | 3.1% | 1.1% | ||
| Q2 25 | 3.0% | 0.8% | ||
| Q1 25 | 2.1% | 0.9% | ||
| Q4 24 | 4.1% | 1.1% | ||
| Q3 24 | 3.1% | 0.8% | ||
| Q2 24 | 2.8% | 0.7% | ||
| Q1 24 | 3.2% | 1.0% |
| Q4 25 | 2.52× | 1.59× | ||
| Q3 25 | 1.79× | 2.29× | ||
| Q2 25 | 1.26× | 1.49× | ||
| Q1 25 | 0.38× | 3.40× | ||
| Q4 24 | 3.54× | 4.29× | ||
| Q3 24 | 1.77× | 1.82× | ||
| Q2 24 | 0.77× | 2.43× | ||
| Q1 24 | 0.26× | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SYK
| Medical | $1.3B | 18% |
| Endoscopy | $1.1B | 16% |
| Traumaand Extremities | $1.1B | 15% |
| Instruments | $925.0M | 13% |
| Knees | $749.0M | 10% |
| Neuro Cranial | $669.0M | 9% |
| Neurovascular | $539.0M | 8% |
| Hips | $499.0M | 7% |
| Other Orthopaedics | $267.0M | 4% |
| Spine | $8.0M | 0% |
USFD
| Product One | $3.5B | 36% |
| Product Two | $1.7B | 17% |
| Product Three | $1.7B | 17% |
| Product Four | $985.0M | 10% |
| Product Five | $901.0M | 9% |
| Product Six | $580.0M | 6% |
| Product Seven | $485.0M | 5% |
